Just won an award.....very Isable..(if you can put it that way)..another of Robbie Burns clever stock picks....decided myself to join in...not sure how high this could go but looking good at the moment !.

LONDON (SHARECAST) - Optos is a Scottish medical technology company that makes scanning devices allowing early detection of cataracts, glaucoma or retinal detachment. Tempus in The Times writes that operating profits for the year to September are set to beat market forecasts of 22.3m dollars. In addition, its management have good form. Chief Executive Roy Davis previously ran Gyrus, which was sold for 935m pounds and Peter Fellner, the Chairman built Celltech, which fetched 1.5bn pounds. Numis has a price target of 300p and they are “worth tucking away.”

OPTS OPTOS

Some fantastic broker targets on OPTS

Optos Broker Views
Date Broker Recommendation Price Old target price New target price Notes

15 Oct Canaccord Genuity Buy 210.50 306.00 306.00 Retains
15 Oct Investec Hold 210.50 202.00 202.00 Retains
15 Oct Numis Buy 210.50 300.00 300.00 Reiterates
15 Oct Panmure Gordon Buy 210.50 230.00 320.00 Upgrades
15 Oct Jefferies International Buy 210.50 270.00 280.00 Retains

NORWICH & PETERBOROUGH BUILDING SOCIETY

OPTS OPTOS

Just looked at robbies tip from
yesterday...... (burns)

I've made decent money from Optos (OPTS) over a couple of years, if you buy it at the right time it can really move up. I thought the statement that came out on the day of the seminar to be very decent - its Daytona technology looks to be very decent and sales could start bringing in some nice profits.

I bought some Optos as the market opened at 205 and a tiny smidge.

Sounds good goldfinger. :-))

Optos has strong sales in sight. Retinal diagnostics specialist continues to demonstrate strong underlying sales and profit momentum. Mondays trading statement (15 Oct) revealed sales for the year to September would exceed $190 million. This is an annual rise of 32% and beats market expectations by a handy 5%. As a result, analysts expect the Dunfermline-based concern, which makes and sells retinal imaging and diagnostic devices, to report an operating profit above the $22.3 million market consensus. The £141 million caps progress has been driven by an 11% increase in volumes to 4,700 units. This has in turn helped by the Daytona retinal scanner. Optos sold 329 of these devices by the end of the year. 85% of which were in the US. The new product detects high blood pressure and certain cancers. Concensus forecasts for fiscal 2013 which call for a 24% increase in earnings per share to 15.3p, a number which puts the stock on a price/earnings ratio (PE) of just 13.7 times .Opus reports full year figures on 21 November.

Dunfermline-based Optos makes devices that show up certain forms of eye disease, including those caused by diabetes, earlier than rival technology. Prospects for the next few years are strong, chief executive Roy Davis is ambitious and at 2071⁄2p, the shares look attractive. Until this year, the group’s devices were extremely large and rather unwieldy, particularly for small surgeries or opticians. Now Optos has started selling a desktop machine, Daytona, which looks sleeker, works more effectively than older models and is expected to prompt a surge in sales. Analysts expect that Optos will have sold at least 6,000 devices by the end of next year, including Daytona and older machines. Profits are expected to rise from £14.9m this year to about £16.1m in 2013 and £21.7m the following year. Optos shares are 2071⁄2p and should increase materially over the next two years. By 2020, 75m people will be blind worldwide unless preventative measures are taken. Optos machines can reduce the chance of blindness and the new Daytona devices should prove particularly popular to eye specialists the world over. This is a Scottish company with a world-beating technology. Buy, The Financial Mail on Sunday´s Midas column says.

Tipped by Midas in Sunday Mail....


MIDAS SHARE TIPS: Great outlook for eye imaging firm OptosBy Joanne Hart

PUBLISHED: 22:22, 20 October 2012 | UPDATED: 22:22, 20 October 2012
Comments (0) Share

..By 2020, 75million people will be blind worldwide unless preventative measures are taken. However, many conditions can be treated or cured if they are caught in time.

Dunfermline-based Optos makes devices that show up certain forms of eye disease, including those caused by diabetes, earlier than rival technology.

The company is growing fast and last week defied the prevailing economic gloom, saying its profits for the year to September 30 would be higher than expected. Prospects for the next few years are strong, chief executive Roy Davis is ambitious and at 2071⁄2p, the shares look attractive.

Eye flyer: The Daytona model is expected to prompt a surge in sales
Optos was founded by Douglas And-erson in 1992 after his five-year-old son went blind in one eye because a detached retina was detected too late.

A design consultant by background, Anderson put together a team of engineers to develop a machine that could analyse more of the retina in one go without subjecting patients to painful, time-consuming examinations.

The first such device came on the market in 1999 and Optos floated on the Stock Exchange seven years later. The first few years were tough but in 2008, Davis joined as chief executive and set about turning Optos from a company with clever ideas to a commercially astute, profitable business.

Davis was formerly at the helm of medical devices group Gyrus, where he drove a substantial increase in sales and profits before it was taken over for nearly £1billion. He is hoping to deliver similar growth at Optos.

The firm’s devices take what are known as optomaps – wide-field, digital images of the retina that help opticians and other eye specialists to see much more of the retina than conventional machines. Many eye diseases are often seen first at the edge of the retina.
But other diseases, such as diabetes, high blood pressure and even certain cancers can also be detected from changes at the retina’s edge. Optos is the only company whose machines instantly provide this wide-angle view, so the potential is clear. The firm has sold 4,700 machines but Davis is hoping to take this up to more than 20,000.

Most Optos devices are made in Scotland, but research shows the British spend more money looking after their teeth than their eyes, so Optos has sold only 150 devices in Britain. In other parts of the world, such as the US, Canada and Japan, they take eye care more seriously.
Most Optos machines are in North America and last year alone they carried out five million optomaps. This figure is likely to rise considerably over the next few years. Until this year, the group’s devices were extremely large and rather unwieldy, particularly for small surgeries or opticians.

Now Optos has started selling a desktop machine, Daytona, which looks sleeker, works more effectively than older models and is expected to prompt a surge in sales.

The new machines, which cost about £50,000, are cheaper to produce as well, so Optos can sell them at a lower cost and still make more money.

Analysts expect that Optos will have sold at least 6,000 devices by the end of next year, including Daytona and older machines. Profits are expected to rise from £14.9million this year to about £16.1million in 2013 and £21.7million the following year.

Midas verdict: Optos shares are 2071⁄2p and should increase materially over the next two years. Eye disease is increasing as the population ages and diabetes becomes more prevalent. Optos machines can reduce the chance of blindness and the new Daytona devices should prove particularly popular to eye specialists the world over. This is a Scottish company with a world-beating technology. Buy.



Read more: http://www.thisismoney.co.uk/money/investing/article-2220663/MIDAS-SHARE-TIPS-Great-outlook-eye-imaging-firm-Optos.html#ixzz29xg9jTQV
Follow us: @MailOnline on Twitter | DailyMail on Facebook

OPTS OPTUS

Trades on a forward P/E of just
over 12 to 2013.

Derd cheap.

RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £41.34m £30.66m £29.29m
EBIT £25.36m £15.28m £17.18m
Dividend Yield % % %
Dividend Cover x x x
PER 6.02x 14.00x 12.19x
PEG 0.05f -0.25f 0.82f
Net Asset Value PS 64.56p 95.47p 110.82p

Off to a hum dinger.

Just about breaking out.

OPTS OPTUS

Some lofty Broker SP targets for
this company......

Date Company Name Broker Rec. Price Old target price New target price Notes

15 Oct Optos PLC Canaccord Genuity Buy 212.50 306.00 306.00 Retains
15 Oct Optos PLC Investec Hold 212.50 202.00 202.00 Retains
15 Oct Optos PLC Numis Buy 212.50 300.00 300.00 Reiterates
15 Oct Optos PLC Panmure Gordon Buy 212.50 230.00 320.00 Upgrades
15 Oct Optos PLC Jefferies International Buy 212.50 270.00 280.00 Retains

NORWICH & PETERBOROUGH BUILDING SOCIETY

I'm in GF despite the spread.

Plenty left in this one Chris. Technology is out on its own. Biggest chunk of stock ive held for months.

Agree mate I've bought a few for long term.

A p/e of 12 plus, blimey Ive seen these type of medical tech stocks with P/es of 50 plus to 75 or more.

OPTOS OPTS


Fallen back a little bit on
intraday chart usually comes
with a big run to day end....

Brokers like it.....

Optos PLC
FORECASTS 2012 2013

Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)
Panmure Gordon
19-10-12 BUY 16.27 17.58 22.24 23.97
Peel Hunt
17-10-12 HOLD 13.74 13.38 9.22 8.99
Numis Securities Ltd
15-10-12 BUY 15.04 14.17 16.22 14.73
Canaccord Genuity Ltd
15-10-12 BUY 15.09 14.13 20.29 19.91
Shore Capital
12-10-12 HOLD 15.60 15.14 18.50 17.98
Investec Securities
05-10-12 HOLD 14.68 13.12 16.62 15.62
N+1 Singer
25-09-12 BUY 17.74 17.72 19.36 18.86
Nomura Code
02-08-12 BUY 11.51 10.94 17.33 16.44

2012 2013
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Consensus 15.21 14.82 17.37 17.03
1 Month Change 0.52 0.47 -0.73 -0.59
3 Month Change 1.08 1.16 -0.28 -0.06


GROWTH
2011 (A) 2012 (E) 2013 (E)

Norm. EPS 114.56% -57.00% 14.86%
DPS % % %

INVESTMENT RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £41.34m £30.66m £29.29m
EBIT £25.36m £15.28m £17.18m
Dividend Yield % % %
Dividend Cover x x x
PER 6.02x 14.00x 12.19x
PEG 0.05f -0.25f 0.82f
Net Asset Value PS 64.56p 95.47p 110.82p

A few days historical.

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759 http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759

Worth a read.....

http://www.bbc.co.uk/news/uk-scotland-scotland-business-19949157

A buy in this weeks shares publication. The retinal diagnostics specialist has boosted sales by 32% this year. Now with the US market accounting for 80% of sales of its new Daytona scanning machine, expect more growth.